Indication: Hematological Malignancies
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Leukemia
Line of Therapy: 2nd Line
Drug Study
Principal Investigator: Don Stevens, M.D.Norton Cancer Institute
Sponsor: BeiGene, Ltd
Learn more at ClinicalTrials.gov
Email for more information: Heme-NCIResearch@nortonhealthcare.org
